Klorhexidin Fresenius Kabi (Chlorhexidine Acetate)

Chlorhexidine acetate exerts its effect by binding to the negatively charged components of bacterial cell walls and disrupting the cytoplasmic membrane. This increases membrane permeability, causing leakage of intracellular contents, loss of metabolic control and ultimately cell death. The action is rapid, concentration‑dependent and effective against a wide range of microorganisms.

The appropriate amount of Klorhexidin Fresenius Kabi is determined by the prescribing clinician based on the specific indication, patient age, skin area to be treated and local practice guidelines. Healthcare professionals select the concentration and volume that best achieve antiseptic effect while minimizing irritation.

Safety data for chlorhexidine acetate in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when clearly needed and after a risk‑benefit assessment by a qualified healthcare provider. Breastfeeding mothers should consult their physician before use.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the sales team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Chlorhexidine acetate offers rapid, persistent antimicrobial activity and is less irritating to skin than many alcohol‑based preparations. Compared with povidone‑iodine, chlorhexidine provides a broader spectrum against Gram‑negative bacteria and has a longer residual effect, but it does not cover spores as effectively. Choice of antiseptic depends on the clinical context, patient tolerance and institutional protocols.

Store the product at room temperature below 25 °C, in its original container, protected from direct light and moisture. Do not freeze the solution. Ensure the cap is tightly closed to maintain stability and prevent contamination.

Apply a thin layer of the solution to clean, dry skin using a sterile gauze or applicator pad. Allow it to air‑dry for the time recommended by the clinician, usually a few minutes, before proceeding with the procedure or covering the area. Do not rinse unless instructed, and avoid contact with eyes, ears or mucous membranes.

Serious adverse reactions, although rare, include anaphylaxis, severe allergic dermatitis, Stevens‑Johnson syndrome and toxic epidermal necrolysis. Immediate medical attention is required if signs of systemic allergy such as difficulty breathing, swelling of the face or throat, or widespread skin blistering occur after application.

Individuals with a known hypersensitivity to chlorhexidine or any component of the formulation should avoid using the product. It is also contraindicated on mucous membranes, deep puncture wounds, or extensive open burns, where systemic absorption could be increased. Pregnant or breastfeeding women should only use it if the benefit outweighs potential risk, as determined by a healthcare professional.